Chiroscience sued by Dutch drugs company
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.CHIROSCIENCE, the Cambridge-based biotechnology company, is being sued in the High Court by a Dutch pharmaceuticals company, which claims Chiroscience is responsible for delays in the launch of one of its drugs.
Merck Generics claims in a writ issued by its subsidiary, Resolution Chemicals, in February 1998 that Chiroscience broke an agreement to supply S-Naproxen, a non-steroid anti-inflammatory drug. MG claims that Chiroscience assigned its supply obligations to an Indian company and later refused to supply S-Naproxen altogether.
It claims it was therefore unable to distribute a new anti-inflammatory drug in tablet form in Canada and the US last year, and wants Chiroscience to pay for the supposed lost sales.
MG declined to give further details of the action. The writ says the group's share of the US and Canadian market for the drug "would have been significantly greater than is now anticipated".
The group is also suing for over pounds 593,000 to cover expenses incurred in seeking an alternative supply. In addition, it is seeking damages and an undisclosed sum to cover associated labour costs. In its annual report published last month Chiroscience says it strongly refutes the allegation and is vigorously defending its position. It denies breaching the agreement. It says it cannot assess the financial impact of an adverse ruling because Resolution's damages have not been particularised. Chiroscience did not refer to the action in 1998's annual report published in May last year.
Resolution Chemicals acquires or manufactures bulk chemicals for distribution to MG's subsidiaries. Chiroscience agreed a supply deal for S-Naproxen with Resolution in May 1996. Resolution claims Chiroscience unexpectedly transferred its obligations to Shasun Chemicals and Drugs, an Indian company, in May 1997 and two months later refused to supply S-Naproxen. It says it had to revise its applications to various regulatory authorities to take account of the switch of supplier.
Chiroscience says Resolution was supportive of the switch and the supplier could have been changed.
MG is unconnected to US pharmaceuticals giant Merck.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments